With a median follow-up of 27 months (range 6–69), no local failures were observed, our progression-free survival rates were 43.6% and 23% at one and 2 years, respectively, while 1 and 2-year overall survival rates were both 70%. Most frequent primary tumors were ovarian cancer in 42.5% and endometrium cancer in 42.5%. ResultsĪ total of 63 oligometastases were treated from December 2014 to February 2021. Univariate and multivariate analyses were performed for assessing any potential predictive factor for clinical outcomes. Data were retrospectively collected and analyzed. Toxicity was retrospectively collected according to CTCAE v4.0. Radiotherapy was delivered in 3–10 fractions with VMAT-IGRT technique. This study reports a preliminary assessment of clinical outcomes in a cohort of 40 patients with oligometastatic gynecological neoplasms. The use of stereotactic radiotherapy (SBRT) for oligometastases is supported by several literature studies, but in the setting of gynecological malignancies, this scenario remains quite unexplored.

Free age progression